Citations

Clear

16280 citation(s) found for "Yu, David".

982: EXTERNAL VALIDATION OF THE FRASER EQUATION TO ESTIMATE FREE VALPROATE CONCENTRATION IN THE ICU
Brown, Caitlin S. , Liu, JiTong , Riker, Richard R. , Lopez, Natasha , Gagnon, David J. , Webb, Andrew , Rosenthal, Eric S.

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001102592.08813.34 Get It

Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes
Claveau, Jean‐Sébastien , Kapoor, Prashant , Binder, Moritz , Buadi, Francis K. , Cook, Joselle , Dingli, David , Fonder, Amie , Gertz, Morie A. , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L., Kourelis, Taxiarchis , Lacy, Martha Q. , Lin, Yi , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Claveau, Jean-Sebastien , Binder, Moritz , Buadi, Francis K , Cook, Joselle M , Dispenzieri, Angela , Fonder, Amie , Gertz, Morie A , Kourelis, Taxiarchis , Lacy, Martha Q , Leung, Nelson , Warsame, Rahma , Kumar, Shaji K , Dingli, David , Charalampous, Charalampos , Dispenzieri, Angela , Gonsalves, Wilson I. , Hwa, Yi L., Leung, Nelson , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | January 30, 2025 | Volume: 9 | Issue: 7 | Pages: 1559-1570

10.1182/bloodadvances.2024013355 | PMID 39883947 Get It

Abstract In this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then expanded our investigation through a systematic review and meta-analysis of 62 studies, encompassing 3487 patients from the years 1960 to 2022. Our findings reveal that patients with up to 10% clonal plasma cells in their bone marrow (BM), denoted as plasmacytoma +, had a significantly reduced median disease-free survival (DFS) of 15.7 months vs 79 months, P < .05, observed in patients with true solitary plasmacytomas, with no clonal cells in the BM. Risk factors identified for shorter DFS included the presence of clonal plasma cells in the marrow and a difference between involved and uninvolved free light chains of >5 mg/dL. The meta-analysis portion of our study highlighted a male predominance among patients, with a median age of 58 years, and confirmed radiation therapy as the predominant treatment modality. We also found that DFS rates at 3, 5, and 10 years were 66.9%, 55%, and 42.1%, respectively, and noted a significant difference in outcomes between patients with bone and extramedullary plasmacytomas, with the latter group exhibiting better survival rates. This dual-faceted approach provides a thorough overview of survival rates and critical risk factors for patients with plasmacytoma, underscoring the vital role of accurate disease staging at diagnosis and the impact of tumor location on patient prognosis.
Revised Process for ACNS Guidelines Development
Andrade, Edgard , Galloway, Gloria, Hyslop, Ann , Selioutski, Olga , Arnold, Susan T., Drislane, Frank W. , Gloss, David , Marashly, Ahmad , Nuwer, Mark R., Sabau, Dragos , Shahid, Asim, Tatum, William O. , Vengrow, Michael, Wusthoff, Courtney J. , Quraishi, Imran H , Andrade, Edgard , Wusthoff, Courtney J , Selioutski, Olga , Hyslop, Ann , Sinha, Saurabh Kumar , Arnold, Susan T., Arya, Ravindra , Bagić, Anto , Hani, Abeer J. , Kobayashi, Eliane , Park, Jun , San‐Juan, Daniel , Shahid, Asim, Skjei, Karen L. , Vengrow, Michael

Mayo Clinic

Journal of Clinical Neurophysiology | January 30, 2025 | Volume: 42 | Issue: 2 | Pages: 95-100

10.1097/wnp.0000000000001133 | PMID 39883486 Get It

Summary: The development of clinical practice guidelines is an evolving field. In response to the need for consistent, evidence-based medical practice, the American Clinical Neurophysiology Society identified the need to update the Society's guideline development process. The American Clinical Neurophysiology Society Guidelines Committee created an action plan with the goal of improving transparency and rigor for future guidelines and bringing existing guidelines to current standards. This article provides an overview of the new American Clinical Neurophysiology Society standards for the creation of clinical guidance documents, including clinical guidelines, technical standards, and consensus statements. This process is rooted in the importance of clinical guidance documents and their significance in the context of current behests for updated standards for practicing clinical neurophysiology. The need and rationale for updating the guideline development process from its prior state were described. The updated American Clinical Neurophysiology Society categories for clinical guidance and recommendations were defined and compared. Finally, the new process is summarized, focusing on methodologies, authorship, and conflicts of interest.
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
Jacobson, Caron A. , Nikiforow, Sarah , Ahmed, Sairah , Miklos, David B. , Lin, Yi , Lunning, Matthew A. , Hill, Brian T. , Ghobadi, Armin , Hu, Zhen‐Huan , Hemmer, Michael, Zoratti, Michael J. , Vunnum, Suresh, Tsang, Jonathan , Spooner, Clare, Smith, Harry , Fu, Christine, Patel, Anik R. , Miao, Harry , Shahani, Shilpa, Mirjah, Debbie L., Xu, Hairong , Pasquini, Marcelo C. , Ahmed, Sairah , Miklos, David B , Ghobadi, Armin , Zoratti, Michael J , Pasquini, Marcelo , Locke, Frederick L. , Siddiqi, Tanya

Mayo Clinic

Blood Advances | January 30, 2025 | Volume: 9 | Issue: 11 | Pages: 2663-2676

10.1182/bloodadvances.2024013656 | PMID 39883946 Get It

Abstract Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Emerging evidence indicates that delayed CAR T-cell infusion, including prolonged time from leukapheresis to infusion, known as vein-to-vein time (V2Vt), may adversely impact clinical outcomes. We conducted a systematic literature review (SLR) and meta-analysis to identify differences in V2Vt in patients with R/R LBCL treated with axi-cel, tisa-cel, or liso-cel. The impact of V2Vt (<28 days vs ≥28 to <40 days vs ≥40 days) on effectiveness and safety outcomes was evaluated in patients treated with axi-cel enrolled in a post-authorization safety study using the Center for International Blood and Marrow Transplant Research data. SLR and meta-analysis showed that patients treated with axi-cel had the shortest median V2Vt (30.6 days) compared with tisa-cel (48.4 days) or liso-cel (35.9 days). Real-world analysis of patients treated with axi-cel demonstrated that V2Vt ≥40 days was associated with significantly lower complete response rate than V2Vt <28 days (odds ratio [OR], 0.61) or ≥28 to <40 days (OR, 0.66) and significantly worse overall survival than V2Vt <28 days (hazard ratio [HR], 1.33) or ≥28 to <40 days (HR, 1.36). Higher prolonged thrombocytopenia rates were observed in patients with axi-cel V2Vt ≥28 to <40 days or ≥40 days compared with <28 days (OR, 1.44 or 1.95, respectively). Together, these results show the impact of V2Vt on patient outcomes with axi-cel therapy and that earlier infusion with CD19-CAR therapies may be beneficial.
Comparative efficacy and safety of stent retrievers as a bailout strategy following failed contact aspiration technique in acute stroke thrombectomy
Ezzeldin, Mohamad , Hukamdad, Mishaal , Kasem, Rahim Abo , Ezzeldin, Rime , Maier, Ilko , Rai, Ansaar , Jabbour, Pascal , Kim, Joon‐Tae , Howard, Brian M. , Wolfe, Stacey Q , Starke, Robert M., Psychogios, Marios‐Nikos , Dye, Justin , Alaraj, Ali , Yoshimura, Shinichi, Tanweer, Omar , Navía, Pedro , Polifka, Adam , Siddiqui, Fazeel , Brinjikji, Waleed , Dağlıoğlu, Ergün , Williamson, Richard A., Altschul, David , Ogilvy, Christopher S. , Crosa, Roberto , Gory, Benjamin , Kan, Peter , Casagrande, Walter, Chowdhry, Shakeel , Stiefel, Michael , Chaubal, Varun , Spiotta, Alejandro M , Abo Kasem, Rahim , Rai, Ansaar , Wolfe, Stacey Quintero , Shaban, Amir , Alaraj, Ali , Fiorella, David , Navia, Pedro , Cuellar-Saenz, Hugo H , Fragata, Isabel , Mascitelli, Justin R , Osbun, Joshua W , Mokin, Maxim , Matouk, Charles , Brinjikji, Waleed , Altschul, David J , Ogilvy, Christopher S , Crosa, Roberto , Levitt, Michael R , Grandhi, Ramesh , Paul, Alexandra R , Kan, Peter , Spiotta, Alejandro M , Howard, Brian M , Jabbour, Pascal , Alawieh, Ali , Goyal, Nitin , Fiorella, David , Romano, Daniele G, Cuellar, Hugo , Fragata, Isabel , Moss, Mark, Limaye, Kaustubh , Matouk, Charles , Park, Min S, Williamson, Richard, Levitt, Michael R. , Grandhi, Ramesh

Mayo Clinic

Journal of NeuroInterventional Surgery | January 30, 2025 | Volume: 18 | Issue: 2 | Pages: 390-398

10.1136/jnis-2024-022781 | PMID 39884851 Get It

Background The contact aspiration (CA) technique is often used to perform endovascular thrombectomy (EVT) for acute ischemic stroke (AIS); however, rescue strategies are necessary if CA fails to achieve recanalization. This study investigates the outcomes of incorporating stent retriever (SR) thrombectomy in the rescue strategy following failed CA. Methods EVT patients with failed CA attempts were identified from a large multicenter registry and stratified by rescue technique: CA alone or incorporating SR in the rescue strategy. Outcomes included successful recanalization, 90-day functional outcomes (defined by the modified Rankin Scale (mRS) score), symptomatic intracranial hemorrhage (sICH), and 90-day mortality. Results Among 1885 patients with failed CA attempts, conversion to SR was associated with higher recanalization rates (85.2% vs 80.6%; p=0.03), higher rates of second-pass recanalization (31.2% vs 23.4%; p<0.001), and better 90-day outcomes (mRS 0–2: 35.2% vs 29.9%; p=0.04) when compared with repeated CA attempts. Trevo SRs showed higher odds of successful recanalization (adjusted odds ratio (aOR)=1.9; p=0.02), second-pass recanalization (aOR=1.7; p=0.01), and reduced odds of sICH (aOR=0.3; p=0.02). EmboTrap SRs were associated with higher odds of 90-day mortality (aOR=2.6; p=0.004) and sICH (aOR=2.9; p=0.04) and lower odds of recanalization (aOR=0.5; p=0.03). Conclusions Incorporating SR in the rescue strategy after a failed CA improves recanalization rates and functional outcomes. Trevo SRs demonstrated superior efficacy and safety when incorporated into the rescue strategy.
Infection‐Related Hospitalization and Incident Heart Failure: The Atherosclerosis Risk in Communities Study
Molinsky, Rebecca , Shah, Amil M. , Yuzefpolskaya, M. , Yu, Bing , Misialek, Jeffrey R. , Bohn, Bruno , Vock, David M. , MacLehose, Richard F. , Borlaug, Barry A. , Colombo, P.C. , Ndumele, Chiadi E. , Ishigami, Junichi , Matsushita, Kunihiro , Lutsey, Pamela L. , Demmer, Ryan T. , Neumark‐Sztainer, Dianne , Molinsky, Rebecca L , Shah, Amil , Yuzefpolskaya, Melana , Vock, David , Colombo, Paolo C , Borlaug, Barry A , Lutsey, Pamela L , Neumark-Sztainer, Dianne , Demmer, Ryan T

Mayo Clinic

Journal of the American Heart Association | January 30, 2025 | Volume: 14 | Issue: 3 | Pages: No page available

10.1161/jaha.123.033877 | PMID 39883116 Get It

Background The immune response to infections may become dysregulated and promote myocardial damage contributing to heart failure (HF). We examined the relationship between infection‐related hospitalization (IRH) and HF, HF with preserved ejection fraction, and HF with reduced ejection fraction. Methods and Results We studied 14 468 adults aged 45 to 64 years in the ARIC (Atherosclerosis Risk in Communities) Study who were HF free at visit 1 (1987–1989). IRH was identified using select International Classification of Diseases ( ICD ) codes in hospital discharge records and was treated as a time‐varying exposure. HF incidence was defined as the first occurrence of either a hospitalization that included an ICD, Ninth Revision ( ICD‐9 ) discharge code of 428 (428.0–428.9) among the primary or secondary diagnoses or a death certificate with an ICD‐9 code of 428 or an ICD, Tenth Revision ( ICD‐10 ) code of I50 among any of the listed diagnoses or underlying causes of death. We used multivariable‐adjusted Cox proportional hazards models to assess the association between IRH and incident HF, HF with reduced ejection fraction, and HF with preserved ejection fraction. Median follow‐up time was 27 years, 55% were women, 26% were Black, mean age at baseline was 54±6 years, 46% had an IRH, and 3565 had incident HF. Hazard ratio (HR) for incident HF events among participants who had an IRH compared with those who did not was 2.35 (95% CI, 2.19–2.52). This relationship was consistent across different types of infections. Additionally, IRH was associated with both HF with reduced ejection fraction and HF with preserved ejection fraction: 1.77 (95% CI, 1.35–2.32) and 2.97 (95% CI, 2.36–3.75), respectively. Conclusions IRH was associated with incident HF, HF with reduced ejection fraction, and HF with preserved ejection fraction. IRH might represent a modifiable risk factor for HF pathophysiology.
Abstract 85: The Association Between Hourly Systolic Blood Pressure Fluctuations and Outcomes in Patients with Intracerebral Hemorrhage is Time Dependent: Post Hoc Analysis of ATACH-2 Trial.
Baskett, William , Lakhani, Pashmeen, Rabinstein, Alejandro, Suárez, José I. , Steiner, Thorsten , Qureshi, Adnan Iqbal , Lakhani, Pashmeen, Rabinstein, Alejandro A. , Rose, David Z. , Shyu, Chi‐Ren

Mayo Clinic

Stroke | January 30, 2025 | Volume: 56 | Issue: Suppl_1 | Pages: No page available

10.1161/str.56.suppl_1.85 Get It

Background: Systolic blood pressure (SBP) fluctuation is linked to increased death or disability in intracerebral hemorrhage (ICH) patients. We analyzed data from the Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-2 trial to explore whether the association between SBP fluctuation and 90-day outcomes varies with time from randomization. Methods: We calculated hourly SBP fluctuation based on the difference between maximum and minimum SBP during the first 24 hours post-randomization. Logistic regression models assessed the impact of SBP fluctuation on: 1) death or disability (modified Rankin scale [mRS] 4-6 at 90 days); 2) hematoma expansion (>33% increase in volume on 24-hour CT scan); 3) neurological deterioration within 24 hours (defined as ≥2-point decrease on Glasgow Coma Scale or ≥4-point increase on NIH Stroke Scale); and 4) acute kidney injury (AKI) within 72 hours. Adjustments were made for baseline Glasgow Coma Scale score, intraventricular hemorrhage, hematoma volume, and maximum SBP. Results: The hourly SBP fluctuations according to 90-day outcomes (dichotomized into good outcome, mRS 0-3, and poor outcome, mRS 4-6) in 961 patients with ICH are presented in Figure. The SBP fluctuation at 5 hours (p=0.014) and 6 hours (p=0.014) post randomization were significantly associated with death or disability at 90 days, with positive, but not statistically significant associations observed at all other points up to 13 hours after randomization. Risk of neurological deterioration within 24 hours was highly associated with SBP fluctuation, with the largest association observed between 1 (p<0.001) and 5 (p<0.001) hours following randomization, with significant associations observed up to 22 hours following randomization. Risk of hematoma expansion was associated with SBP fluctuation between 3 (p=0.015) and 8 (p=0.002) hours post randomization. Statistically significant associations between SPB fluctuations and risk of AKI were not observed. Conclusions: The first 8 hours following randomization are critical for reducing SBP fluctuations, as this period most strongly influences both short- and long-term outcomes in ICH patients. These findings suggest this time window is crucial for future interventions aimed at controlling SBP in ICH patients.
Abstract TMP60: Using CTP based Disconnectome Mapping to identify optimal candidates for endovascular treatment in acute ischemic stroke.
Brinjikji, Waleed , Kallmes, David F, Carone, Davide , Garrard, James , Zarrintan, Armin , Harston, George , Kallmes, David F.

Mayo Clinic

Stroke | January 30, 2025 | Volume: 56 | Issue: Suppl_1 | Pages: No page available

10.1161/str.56.suppl_1.tmp60 Get It

Background: Identifying optimal candidates for endovascular treatment (EVT) remains an ongoing priority to maximize treatment efficacy. The recent large core trials have called into question the use of infarct volume alone for selecting patients. This study aimed at exploring the feasibility of using routinely acquired Computed Tomography Perfusion (CTP) to capture how lesion location impacts brain connectivity and how this in turn affects the ability to benefit from EVT. Methods: Consecutive patients from a multi-centric stroke imaging registry were included in this study if they had a proven anterior circulation large vessel occlusion (LVO) and available baseline CTP data. Hypoperfusion (Tmax >6 seconds) and ischemic core (relative cerebral blood flow <30%) maps were automatically generated using e-CTP (Brainomix, UK) and used to derive disconnection maps via a DTI template. A voxel-based, multivariate method (Sparse Canonical-Correlation-Analysis – LESYMAPS) was used to explore associations between disconnection maps and NIHSS subitems in recanalized patients. The mismatch between Tmax and core disconnection volumes (disconnection mismatch volume) (Figure 1) was used to predict modified Rankin Scale (mRS) at 3-months using an ordinal shift regression adjusted for age, recanalization status and infarct volume. Results: One-hundred and seventy-one patients were included. The median NIHSS was 16 (11.5 to 22). The total NIHSS was associated with disconnection predominantly within the left basal ganglia, brainstem and corpus callosum. Upper and lower limb deficits (NIHSS 5a, 5b, 6a, 6b) were associated with corticospinal tract disconnection, with negative correlations within the contralateral tracts (Figure 2). Language deficits were associated with left hemisphere tract disconnection, also showing negative correlations within the contralateral tracts. The disconnection mismatch volume was an independent predictor of functional outcome at 3-months (Table 1). Conclusion: The results from this study showed that it is possible to use routinely acquired CTP to capture the effects of stroke lesion on brain connectivity and its impact on functional outcome following recanalization treatment. Such an approach could enable more nuanced treatment selection for patients based on specific neurological deficits.
Abstract 67: How dark is too dark? A multicentric retrospective study exploring the role of Net-Water-Uptake in predicting futile recanalization following mechanical thrombectomy.
Brinjikji, Waleed , Halak, Abdulrahman Al, Václavík, Daniel , Rai, Ansaar, Kallmes, David F, Carone, Davide , Perry, Alistair , Zamarro, Joaquín , Rai, Ansaar , Kallmes, David F. , Harston, George

Mayo Clinic

Stroke | January 30, 2025 | Volume: 56 | Issue: Suppl_1 | Pages: No page available

10.1161/str.56.suppl_1.67 Get It

Background: Acute stroke lesions become more hypodense on non-contrast CT as the ischemic injury matures. Lesions transition to established infarcts at which time recanalization treatment is thought to be futile, if not harmful. As it is not possible to directly quantify the degree of injury progression, eligibility for treatment is determined using temporal criteria. In this study we used an AI approach to segment and quantify the degree of hypoattenuation of acute stroke lesions on baseline CTs, and explored its impact on clinical outcome following mechanical thrombectomy. Methods: Imaging was collected from a multicentric registry (across 4 US and 5 EU sites) of consecutive large vessel occlusion (LVO) stroke patients who underwent mechanical thrombectomy. Baseline NCCT scans were processed using Brainomix 360 to automatically segment the ischemic core. Lesion hypoattenuation was then quantified by in-house software using the mean Net-Water-Uptake (NWU). Multivariate models were used to explore the association between NWU and clinical outcome (3-month modified Rankin scale–mRS), controlling for e-ASPECTS scores, age, and recanalization status. Interaction models were also used to examine the relationship between NWU e-ASPECTS scores. Results: Of the 1363 patients included (age: median 70, IQR: 50-79; 571 females), successful recanalization (mTICI 2b-3) was achieved for 1119 patients. Multivariate analysis found NWU (p=<.001, t=4.62; Fig1) to remain an independent predictor of outcome. There was a significant interaction effect between and ASPECTS score (p=0.029, Fig 2), suggesting that degree of hypoattenuation played a larger role in patients with lower aspects value. In subgroup analysis, NWU was not a significant predictor of outcome in patients that did not achieve successful recanalizion (mTICI 0-2a). Conclusions: These findings suggest that stroke lesion hypodensity measured using NWU might help identify patients at risk of futile recanalization, and that incorporating this information might be more relevant in patients with lower ASPECTS. The ability to determine treatment eligibility using information extracted from routine imaging would allow safe extension of treatment to patients with unclear onset time, and would account for differences in rates of infarct progression.
Abstract WP300: Anticoagulation versus antiplatelet for secondary prevention in embolic stroke of undetermined source: The Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence Study
Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph, Kerrigan, Deborah , Ali, Hamid , Nour, Hassan Aboul , Melkumova, Emiliya , Dumitrascu, Oana M. , Doolittle, Charles, Yahnke, Ian, Sathya, Anvitha , Brown, Samantha , Kang, Jieun, Bowman, Anna, Shahrivari, Mahan, Alvi, Muhammad , Krishnaiah, Balaji , Kam, Wayneho , Farooqui, Mudassir, Rojas-Soto, Diana , Thottempudi, Neeharika, Nedelcu, Simona, Smith, Matthew , Herpich, Franziska , Glover, Patrick , Chahien, Dalia, Sehgal, Siddharth, Linares, Guillermo , Daniel, Jean-Philippe, Kasab, Sami Al , Singh, Eesha , D’Souza, Maria , Gaudio, Elizabeth, Yaghi, Shadi, Omran, Setareh Salehi , Thon, Jesse , Brown, Samantha J , Aboul-Nour, Hassan , Melkumova, Emiliya , Siegler, James E. , Goicoechea, Elena Badillo, Stretz, Christoph , Lineback, Christina , Khasiyev, Farid , Havenon, Adam de , Culbertson, Collin J , Jillella, Dinesh , Doolittle, Charles, Brorson, James R. , Elangovan, Cheran , Sloane, Kelly L , Farooqui, Mudassir , Nahab, Fadi B , Sharma, Richa , Thottempudi, Neeharika , Nedelcu, Simona , Liebeskind, David S. , Daniel, Jean-Philippe, D'Souza, Marissa, Aziz, Yasmin , Yaghi, Shadi

Mayo Clinic

Stroke | January 30, 2025 | Volume: 56 | Issue: Suppl_1 | Pages: No page available

10.1161/str.56.suppl_1.wp300 Get It

Introduction: Four randomized clinical trials have not demonstrated the superiority of anticoagulation over antiplatelet therapy in the prevention of recurrent embolic stroke of undetermined source (ESUS). In this multicenter observational cohort study, we evaluated long-term outcomes associated with various antithrombotic strategies according to potential embolic sources. Methods: A multicenter retrospective observational cohort of consecutive adult patients with ESUS was queried (n=27 sites). Comparisons were made between patients treated with single or combination antiplatelet therapy versus anticoagulation (direct oral anticoagulant, vitamin K antagonist, low molecular weight heparin) with or without antiplatelet therapy initiated within 7 days of stroke. The primary composite outcome of recurrent stroke, major bleeding, or death was assessed using unadjusted and adjusted Cox proportional hazards regression, with clustering by site. Causal inference was assessed using inverse probability of treatment weighted regression adjustment (IPTWRA), accounting for propensity for antiplatelet treatment, with effect estimates summarized as the average treatment effect (ATE) over time (in days). Adjusted models accounted for age, stroke severity, vascular risk factors, and major categories of potential embolic sources. Results: Of the 2201 included patients (n=218 treated with anticoagulation) followed over a median of 564 days (interquartile range [IQR] 154-1124), the median age was 65y (IQR 54-74) and 49.8% were female. Patients treated with anticoagulation were older with more frequent previous stroke, concomitant left ventricular dysfunction, and more severe deficits. Over 4541 person-years of follow-up, the annualized incidence rate of the primary outcome was 14.6% (95% confidence interval [CI], 13.6%-15.8%). Compared to anticoagulation, antiplatelet(s) use was not associated with a lower risk of the primary outcome in the adjusted Cox model (HR 0.91, 95% CI, 0.64-1.29) or in the IPTWRA model (average treatment effect 0.14, 95% CI, -1376.6 to 1376.9). Major bleeding events trended toward significance in the adjusted Cox model (HR 0.51, 95% CI 0.25-1.04) but were no different with IPTWRA (ATE 58.9, 95% CI, -125.4 to 243.2). Conclusions: These results validate the observations of randomized trials indicating a lack of benefit of anticoagulation over antiplatelet therapy in ESUS. A more detailed analysis of heterogeneity of treatment effect is under way.